No Data
No Data
Shanxi C&Y Pharmaceutical Group (300254.SZ): Subsidiary received corporate support funds of 3 million yuan.
On September 11th, GeLongHui announced that its subsidiary, Tibet Shanxi C&Y Pharmaceutical Co., Ltd. (hereinafter referred to as 'Tibet Shanxi'), received a corporate support fund of 3 million yuan allocated by the Tibet Autonomous Region Qinghai Industrial Park Administration on September 9th, 2024, for Tibet Shanxi.
shanxi c&y pharmaceutical group (300254.SZ) intends to acquire 36% equity of Jiayi Pharmaceutical for 0.264 billion yuan to consolidate its controlling position.
Shanxi C&Y Pharmaceutical Group (300254.SZ) issued an announcement that the company plans to invest CNY 0.115 billion to establish a wholly-owned subsidiary for special purposes...
Qianyuan Pharmaceutical: 2024 Semi-Annual Report
Qianyuan Pharmaceutical: 2024 Semi-Annual Report Summary
Shanxi C&Y Pharmaceutical Group (300254.SZ) released its semi-annual performance with a net income of 33.5025 million yuan, turning losses into profits compared to the same period last year.
Shanxi C&Y Pharmaceutical Group (300254.SZ) disclosed its 2024 interim report, with the company achieving revenue of 4...
Shanxi C&Y Pharmaceutical Group (300254.SZ): Net income of 33.5025 million yuan in the first half of the year, turning losses around year-on-year.
On August 28, GeLongHui announced the 2024 interim report, with revenue of 401 million yuan during the reporting period, a year-on-year increase of 9.72%; net income attributable to the company's shareholders was 33.5025 million yuan, turning losses into profits year-on-year; net income attributable to the company's shareholders excluding non-recurring gains and losses was 20.0552 million yuan; basic earnings per share was 0.1387 yuan.
No Data
No Data